NEMO-Binding Domain Analog Small Molecules for NF-kB Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small molecule inhibitors of NF-κB activation, such as those targeting the NEMO binding domain, face limitations in stability and biodistribution, leading to ineffective treatment of inflammatory and degenerative diseases due to their short half-life and lack of oral bioavailability.
Innovation Solution
Development of novel NEMO-binding domain analogs (NBDA) compounds that mimic the NBD peptide, specifically designed to disrupt the interaction between NF-κB essential modulator (NEMO) and IκB kinase-β (IKK-β), using structure-based pharmacophore modeling and virtual screening to identify small molecules with improved stability and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NBD peptide is used to block NEMO-IKKβ interaction, then NF-κB activation is inhibited, but the peptide has short half-life and lacks oral bioavailability
Solution Approach 1:
The patent applies parameter changes by transforming the peptide molecule into small molecule compounds with modified chemical parameters. The NBDA compounds exhibit improved pharmacokinetic parameters including extended half-life and oral bioavailability while maintaining the ability to inhibit NF-κB activation through NEMO-IKKβ interaction blocking
Solution Approach 2:
The patent uses copying by creating small molecule analogs that replicate the functional properties of the NBD peptide. The NBDA compounds copy the peptide's ability to bind to the NEMO binding domain and inhibit NF-κB activation, while possessing improved stability and bioavailability characteristics
2Reliability
If NBD peptide is used to treat inflammatory diseases, then NF-κB signaling is inhibited, but synthesis cost is high and oral administration is not feasible
Solution Approach 1:
The patent creates small molecule copies of the NBD peptide that replicate its therapeutic function. The NBDA compounds can be synthesized more economically and administered orally, copying the peptide's mechanism of action while improving manufacturability and administration ease
Solution Approach 2:
The patent substitutes the peptide-based mechanical system with a small molecule chemical system. This replacement enables oral administration and reduces synthesis costs while maintaining the therapeutic effect of blocking NEMO-IKKβ interaction
3Reliability
If small molecule inhibitors target NEMO binding domain, then NF-κB activation is blocked, but stability and biodistribution are insufficient
Solution Approach 1:
The patent applies parameter changes by optimizing the chemical structure of small molecule inhibitors. The NBDA compounds feature modified chemical parameters including enhanced metabolic stability and improved biodistribution properties while maintaining potent NEMO binding domain inhibition
Data Source
AI summary
The invention is directed to a method of inhibiting, within a living cell, the interaction between NF-κB essential modulator (“NEMO”) with IκB kinase-β (IKK-β) at the NEMO binding domain (NBD), comprising exposing the cell to an effective amount or concentration of a compound of the invention, a NEMO-binding domain analog (NBDA). The invention is further directed to a method of treating a condition in a patient, wherein inhibiting the interaction between NF-κB essential modulator (“NEMO”) with IκB kinase-β (IKK-β) at the NEMO binding domain (NBD) is medically indicated, comprising administering to the patient an effective dose of a compound of the invention. Conditions that can be treated by a method of the invention includes muscular dystrophy, asthma, inflammatory bowel disease, multiple sclerosis, Parkinson's Disease, arthritis, diabetes, graft versus host disease, accelerated aging, heart ischemia, cancer, UV-induced skin damage, or an age-related pathology.